Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007.
de Paulis
Tomas
T
lntdp@earthlink.net
D000818:Animals; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D015394:Molecular Structure; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D058825:Serotonin 5-HT1 Receptor Agonists; D016540:Smoking Cessation; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D010879:Piperazines; D058825:Serotonin 5-HT1 Receptor Agonists; D013449:Sulfonamides; C511631:naluzotan